Company Overview
Mainz Biomed N.V. operates within the healthcare sector, specifically focusing on the diagnostics and research industry, where it develops and sells in-vitro diagnostic tests designed for the early detection of cancer in the United States and Europe. The company's core product portfolio includes ColoAlert, a molecular genetic stool test for colorectal cancer, and PancAlert, a stool-based screening test for pancreatic cancer detection. As of the latest data, the enterprise holds a market capitalization of $5.51 million and employs a workforce of 19 individuals to support its research and development operations. With annual revenue recorded at $659,935, the company's financial scale indicates it is a micro-cap entity operating with a very small revenue base relative to its valuation metrics. This limited revenue generation suggests the company is in a pre-profitability stage typical of biotech firms, where significant capital is often required for R&D before achieving substantial commercial scale.
Financial Health
The company reported a trailing twelve-month revenue of $659,935, yet this figure masks a substantial loss with a net income of -$18,971,112 and an EBITDA of -$16,145,343. The massive disparity between the low revenue of approximately $660,000 and the net loss of nearly $19 million reveals an extremely fragile cost structure where expenses vastly outweigh all income generated. Free cash flow stands at -$8,186,486, which indicates a severe lack of financial flexibility and an ongoing burn rate that depletes the company's liquidity reserves. Despite the heavy losses, the company maintains $1.91 million in cash on hand, though this is significantly outweighed by total debt of $3.09 million. The balance sheet is highly leveraged, evidenced by a debt-to-equity ratio of 122.65, meaning the company owes more than twice the value of its shareholders' equity. Liquidity is constrained further by a current ratio of 0.52, which suggests the company possesses fewer current assets than current liabilities, posing a risk of short-term solvency issues. Return on assets is negative at -114.4%, and return on equity is listed as N/A, indicating that management has not yet generated positive returns on the capital invested by shareholders or the asset base.
Valuation Assessment
Valuation metrics for Mainz Biomed N.V. present a mixed picture due to the absence of profitability, resulting in a trailing P/E ratio of N/A and a forward P/E of N/A. The lack of a positive earnings denominator implies that traditional earnings-based valuation models are inapplicable, and the market is pricing the stock based on assets or sales rather than profit potential. The price-to-book ratio is 0.71, suggesting the market values the company at approximately 29% below its book value, which could indicate that the market has discounted the company's asset value or future prospects heavily. Alternative valuation metrics show a price-to-sales ratio of 8.34 and an EV/EBITDA of -0.18, indicating that investors are paying a premium of over eight times revenue for a company that is currently burning cash and generating negative operating earnings. The stock has traded between a 52-week high of $4.80 and a 52-week low of $0.41, with the current price implied to be significantly closer to the low end given the negative EV/EBITDA and lack of earnings. The beta is 0.32, which means the stock exhibits significantly lower volatility than the broader market, moving at roughly one-third the sensitivity of the overall index.
Growth & Income
Revenue growth year-over-year is negative at -44.9%, while earnings growth is N/A due to the company reporting a net loss rather than profit. Since earnings are negative, they are not growing faster than revenue; instead, the company is contracting in terms of revenue while simultaneously expanding its losses, implying a deepening of operational inefficiencies or increased R&D spending relative to sales. The company does not pay a dividend, as indicated by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company reinvests its minimal earnings and cash reserves into growth initiatives, such as developing new diagnostic tests, rather than distributing income to shareholders. The overall growth and income profile reflects a high-risk, high-potential biotech narrative where current financial metrics are driven by research and development expenditures rather than profitable commercial expansion.